Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

NCT05075603 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Diffuse Large B-cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent Diffuse Large B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Efineptakin alfa
DRUG: Tisagenlecleucel
DRUG: Axicabtagene ciloleucel
DRUG: Lisocabtagene Maraleucel

Sponsor

NeoImmuneTech